First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression
Beckley Psytech’s Phase IIa study will explore the safety, efficacy and pharmacokinetics of a single dose of BPL-003, in combination with psychological support, in patients with Treatment Resistant Depression (TRD).